SignatureFD’s Tourmaline Bio TRML Stock Holding History

SignatureFD’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-54	Closed	-$821	–	3431
2025 Q1	$821	Hold	54	–	–	﹤0.01%	3087
2024 Q4	$1.09K	Hold	54	–	–	﹤0.01%	3007
2024 Q3	$1.39K	Buy	+54	New	+$901	﹤0.01%	2928

Other funds holding TRML

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

SignatureFD's TRML Position: Q2 2025 in Review

SignatureFD sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 54 shares — an estimated $821 sold.

SignatureFD first reported a position in TRML in Q3 2024 and held it in 3 quarters. The position peaked at $1.39K in Q3 2024. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

SignatureFD reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
SignatureFD sold 54 Tourmaline Bio shares in Q2 2025, an estimated $821.
SignatureFD first reported a position in Tourmaline Bio in Q3 2024 and held it in 3 quarters.
SignatureFD's Tourmaline Bio position peaked at $1.39K in Q3 2024.
108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on SignatureFD's 13F filing for Q2 2025, filed 16 Jul 2025.